Danish pharmaceutical giant Novo Nordisk says about 13 million Australians are living with obesity or are overweight, potentially making half the population candidates for its weight-loss drugs Ozempic and Wegovy.
The federal government is reluctant to reimburse the so-called GLP-1 drugs for weight loss, but Novo Nordisk says many Australians would be willing to pay the out-of-pocket costs for its blockbuster medicines, which can be up to $460 a month.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.